Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Assets (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Current Assets for 17 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 7.2% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 7.2% year-over-year, with the annual reading at $1.2 billion for FY2025, 7.2% up from the prior year.
  • Current Assets hit $1.2 billion in Q4 2025 for Integra Lifesciences Holdings, up from $1.1 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.4 billion in Q1 2024 to a low of $1.0 billion in Q3 2023.
  • Historically, Current Assets has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2021.
  • Biggest five-year swings in Current Assets: surged 37.51% in 2024 and later fell 21.79% in 2025.
  • Year by year, Current Assets stood at $1.2 billion in 2021, then grew by 0.67% to $1.2 billion in 2022, then fell by 8.91% to $1.1 billion in 2023, then rose by 2.23% to $1.1 billion in 2024, then grew by 7.2% to $1.2 billion in 2025.
  • Business Quant data shows Current Assets for IART at $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.